Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.

Advertisers are turning to creative strategies to capture attention ahead of the showdown between the Philadelphia Eagles and ...

Phenotyping children with asthma based on rhinoconjunctivitis symptoms shows that rhinoconjunctivitis may not always be allergy driven.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...